A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy
Authors:
- 1 December 1988
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 116 (6) , 1826-1832
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Coronary risk prediction in adults (The Framingham Heart Study)The American Journal of Cardiology, 1987
- Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded?JAMA, 1986
- Double‐blind comparison of the effects of long‐term treatment with doxazosin or atenolol on serum lipoproteins.British Journal of Clinical Pharmacology, 1986
- Multicentre 12‐week double‐blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.British Journal of Clinical Pharmacology, 1986
- Need to prevent and control high-normal and high-blood pressure, particularly so-called “mild” hypertension: Epidemiological and clinical dataPreventive Medicine, 1985
- Antihypertensive Therapy and LipidsArchives of internal medicine (1960), 1985
- The Hypertension‐CHD DilemmaActa Medica Scandinavica, 1985
- Plasma Lipoproteins, Antihypertensive Drugs and Coronary Heart DiseaseJournal of Cardiovascular Pharmacology, 1985
- Intervention for the prevention and control of hypertension and atherosclerotic diseases: United States and international experienceThe American Journal of Medicine, 1984
- High Density Lipoproteins and AtherosclerosisAnnual Review of Medicine, 1980